Related Experiment Videos
Creatine phosphate suppresses ventricular arrhythmias resulting from coronary artery ligation
Insights
Creatine phosphate significantly reduced life-threatening ventricular arrhythmias in a rat model of acute myocardial ischemia. This cardiac protection was observed even when administered hours before coronary artery ligation.
Area of Science:
- Cardiology
- Pharmacology
- Physiology
Background:
- Acute myocardial ischemia frequently leads to life-threatening ventricular arrhythmias.
- Creatine phosphate is investigated for its potential cardioprotective effects.
Purpose of the Study:
- To evaluate the efficacy of creatine phosphate in preventing ventricular arrhythmias during acute myocardial ischemia in a rat model.
- To investigate the electrophysiological mechanisms underlying creatine phosphate's protective effects.
Main Methods:
- Administration of creatine phosphate (50 and 100 mg/kg) into the left ventricle of pentobarbitone-anesthetized male rats.
- Induction of acute myocardial ischemia via coronary artery ligation.
- Electrophysiological studies on isolated papillary muscles.
Main Results:
- Creatine phosphate markedly reduced ventricular ectopic beats, tachycardia, and fibrillation.
- Protection was evident even with a 1-2 hour delay between administration and ischemia.
- Electrophysiological studies showed decreased maximum depolarization rate and prolonged action potential duration.
Conclusions:
- Creatine phosphate demonstrates significant efficacy against early post-infarction ventricular arrhythmias in rats.
- Prolongation of the cardiac action potential may contribute to its anti-arrhythmic effects.
- The role of energy production maintenance in these effects requires further investigation.
Abstract:
The effects of various doses of creatine phosphate have been examined in a rat model of acute myocardial ischaemia. When given directly into the lumen of the left ventricle in pentobarbitone-anaesthetised male rats, creatine phosphate (50 and 100 mg/kg) markedly reduced the incidence of ventricular ectopic beats, and especially the incidence and duration of ventricular tachycardia and fibrillation which normally resulted from acute coronary artery ligation in this model. This protection was observed even if 1 of 2 h elapsed between creatine phosphate administration and coronary artery ligation. Electrophysiological studies on papillary muscles removed from rats 1 h after administration showed that creatine phosphate both decreased the maximum rate of depolarisation and prolonged the duration of the action potential. These results confirm our previous work in dogs that creatine phosphate is effective against early postinfarction ventricular arrhythmias, at least if given locally. It is suggested that these effects are due, at least in part, to a prolongation of the cardiac muscle action potential. Whether this is the result of maintaining energy production early in myocardial ischaemia is unclear.